Biomea Fusion is trading 5.06% down now at $1.69 after opening lower amid a broader biotech selloff tied to disappointing pelacarsen trial results from Ionis Pharmaceuticals.
- The sector is also under pressure from analyst downgrades and weaker sentiment toward commercial-stage biotechnology companies.
- No new company-specific announcement, financing, regulatory decision, or clinical readout was identified for September 15, 2026.
- Biomea Fusion is scheduled to present at the H.C. Wainwright conference at 11:00 a.m. ET.